Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast

Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking action, montelukast has been proposed to have secondary properties. This study aimed investigate modulatory of expression major genes involved in airway inflammation (TNF, IL6) and remodeling (MMP9, TGFB1) response lipopolysaccharide (LPS) vitro. The selected was measured by quantitative real-time polymerase chain reaction 0h 24h after LPS stimulation cells pretreated with montelukast. Montelukast found significantly attenuate increased TNF IL6 gene expression, mild MMP9 no TGFB1 upon LPS. results our indicate that patients would adequate acute microorganism-induced inflammation, so additional effects should be better exploited.